What does cannabis research say about peripheral neuropathy? We've analyzed 4 peer-reviewed studies to give you an honest, evidence-based overview.
Multiple high-quality studies support cannabis for this condition.
Study found evidence of effectiveness
* Outcomes are based on our curated selection of research reviews. Individual study quality varies.
About This Research Summary: The information below aggregates findings from multiple peer-reviewed studies on cannabis and peripheral neuropathy. This is for educational purposes only.
Research summaries are our interpretations of published studies. Individual responses to cannabis vary significantly. These findings do not guarantee similar results for any individual.
Study data sourced from PubMed®. Not evaluated by the FDA. See our Research Content Policy.
Neuropathy (peripheral neuropathy) refers to damage to the peripheral nerves, causing pain, numbness, tingling, and weakness—typically in the hands and feet. It affects an estimated 20 million Americans and has numerous causes, including diabetes (the most common), chemotherapy, HIV, autoimmune diseases, and sometimes no identifiable cause. Neuropathic pain is notoriously difficult to treat. It's often described as burning, shooting, or electric shock-like, and doesn't respond well to typical pain medications like NSAIDs or even opioids. Standard treatments include anticonvulsants (gabapentin, pregabalin), antidepressants (duloxetine, amitriptyline), and topical agents—but many patients find these only partially effective. Neuropathic pain is one area where cannabis research has shown relatively consistent positive results, making it a particularly promising application of medical cannabis.
Cannabinoids appear particularly well-suited for neuropathic pain because they work through multiple mechanisms relevant to nerve pain. CB1 receptors are present throughout the nervous system, including in areas involved in pain processing. THC modulates pain signaling in the brain and spinal cord, changing how neuropathic pain signals are perceived. This central mechanism may explain why cannabis can help when peripheral treatments fail. CBD has anti-inflammatory and neuroprotective properties that may be relevant to neuropathy. It may also enhance the body's own endocannabinoids, which help regulate pain perception. Research suggests cannabinoids may help both the pain and the "unpleasantness" of neuropathic pain—patients often report that even when pain is still present, it bothers them less and interferes less with daily activities.
Note: This information summarizes research findings and is not medical advice. Consult a healthcare provider before using cannabis for any medical condition.
Based on our analysis of peer-reviewed studies on cannabis and peripheral neuropathy:
Based on research, these cannabinoids show the most promise for peripheral neuropathy:
Combination products have the best evidence base. THC provides direct pain relief while CBD may add anti-inflammatory and neuroprotective effects. Sativex (1:1 THC:CBD) has been specifically studied for neuropathic pain.
THC alone is effective for neuropathic pain, with several positive controlled trials. It provides direct analgesic effects but comes with more psychoactive side effects than combination products.
CBD alone has less evidence for neuropathic pain than THC. It may help with inflammation and as an adjunct, but most patients with significant neuropathic pain need THC-containing products.
Individual responses vary. Work with a healthcare provider to determine the best approach for your situation.
Neuropathic pain often requires moderate doses of cannabis for meaningful relief. Studies showing benefit have used 2.5-15mg THC or equivalent, though individual needs vary widely. Start with 2.5-5mg THC and titrate up gradually every few days. The goal is finding the minimum effective dose—higher doses don't necessarily provide more relief but do cause more side effects. For continuous neuropathic pain, scheduled dosing with oral products provides more consistent relief than as-needed use. Many patients use a longer-acting oral product for baseline relief and inhaled cannabis for breakthrough pain. Neuropathy often coexists with conditions like diabetes—monitor blood sugar if using cannabis, as some patients experience changes in appetite and eating patterns.
Dosing information is based on clinical research and is for educational purposes only. Optimal dosing varies by individual, product formulation, and administration method. Always start with the lowest effective dose and titrate slowly under medical supervision.
When considering cannabis for peripheral neuropathy, be aware of these potential concerns:
Discuss these considerations with your healthcare provider before starting cannabis therapy.
A 2018 Cochrane review found cannabis-based medicines more effective than placebo for neuropathic pain, with patients 1.5x more likely to achieve 50%+ pain reduction. Neuropathic pain has some of the strongest evidence for medical cannabis.
Source: Mucke et al., Cochrane Database, 2018 (PMID: 29513392)
A meta-analysis of 16 studies with 1,750 patients found consistent benefit for neuropathic pain. Both inhaled and oral cannabis have shown efficacy in controlled trials. Neuropathy is considered one of the best-supported conditions for cannabis.
Source: Multiple meta-analyses including Mucke et al., 2018
Diabetic neuropathy is a type of peripheral neuropathy. Research on neuropathic pain generally includes diabetic patients and shows consistent benefit. Cannabis may help manage pain, though diabetics should monitor blood sugar.
Source: Included in neuropathic pain meta-analyses
Standard first-line treatments include gabapentin, pregabalin, and duloxetine. A 2018 Cochrane review found cannabis provides additional benefit for neuropathic pain. Many patients use cannabis alongside conventional treatments.
Source: Mucke et al., Cochrane Database, 2018 (PMID: 29513392)
Common questions about cannabis for peripheral neuropathy:
This scoping review found cannabis has been shown useful for both acute and chronic pain, with the strongest evidence for MS-related pain and as an adjunct in cancer pain. However, evidence is weak for neuropathic pain, rheumatic conditions, and headache, and there is no strong evidence for using cannabis to reduce opioid use.
Cannabinoids provide moderate pain relief for chronic neuropathic pain, with patients 1.5 times more likely to experience 30% or greater pain reduction compared to placebo.
This Cochrane review of 16 studies found that cannabis-based medicines provide modest pain relief for neuropathic pain—about 1 in 11 patients achieve meaningful improvement. However, side effects are common, with nervous system and psychiatric effects occurring more frequently than with placebo.
This rigorous meta-analysis of 104 studies found cannabis provides modest pain relief—about 1 in 24 patients benefit—but with a high side effect burden: 1 in 6 experience harm. The authors concluded it "seems unlikely that cannabinoids are highly effective medicines" for chronic pain.
Our reviews are just a starting point. Browse thousands more studies on PubMed for peripheral neuropathy.
Neuropathy typically qualifies under chronic pain or intractable pain provisions in most states. Some states list neuropathic pain specifically. Medical documentation of diagnosis and failed conventional treatments strengthens applications.
Research Summary Disclaimer
This content represents our interpretation of published scientific research for educational purposes. It should not be used to make treatment decisions without consulting a qualified healthcare provider. Individual results may vary from study findings.
FDA Notice
These statements have not been evaluated by the FDA. Cannabis is not intended to diagnose, treat, cure, or prevent any disease. The FDA has not approved cannabis for any medical condition except specific prescription medications.
Copyright & Fair Use
Research summaries are provided under fair use (17 U.S.C. § 107) for educational purposes. We provide brief summaries with attribution, not full reproductions. All studies remain the intellectual property of their respective authors and publishers.
For complete information, see our Terms of Use and Research Content Policy.
